T
TG Therapeutics, Inc. (TGTX)
NCM – Real Time Price. Currency in USD
42.54
-0.60 (-1.39%)
At close: May 12, 2026, 4:00 PM EDT
42.44
-0.10 (-0.24%)
After-hours: May 12, 2026, 7:06 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
42.54
-0.60 (-1.39%)
At close: May 12, 2026, 4:00 PM EDT
42.44
-0.10 (-0.24%)
After-hours: May 12, 2026, 7:06 PM EDT
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
| Name | Position |
|---|---|
| Mr. Adam Waldman | Chief Commercialization Officer |
| Mr. Michael S. Weiss Esq., J.D. | Chairman, CEO & President |
| Mr. Sean A. Power CPA | CFO, Corporate Secretary & Treasurer |
| Ms. Jenna Bosco | Senior Vice President of Corporate Communications |
| Date | Type | Document |
|---|---|---|
| 2026-05-06 | 8-K | tgtx20260227_8k.htm |
| 2026-05-06 | 10-Q | tgtx20260331_10q.htm |
| 2026-04-30 | DEF 14A | tgtx20260301_def14a.htm |
| 2026-03-20 | 8-K | tgtx20260319_8k.htm |
| 2026-02-27 | 10-K | tgtx20251231_10k.htm |
| 2026-02-26 | 8-K | tgtx20251112_8k.htm |
| 2026-01-13 | 8-K | tgtx20260113_8k.htm |
| 2025-11-05 | 10-Q | tgtx20250930_10q.htm |
| 2025-11-03 | 8-K | tgtx20250909_8k.htm |
| 2025-08-08 | S-8 | tgtx20250722_s8.htm |